Trials / Completed
CompletedNCT00089648
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
A Phase 2 Study Of SU011248 In The Treatment Of Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether sunitinib (SU011248) has activity and is safe in patients with renal cell carcinoma (RCC) who have failed prior therapy with bevacizumab (Avastin) -based treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | 50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-01-01
- Completion
- 2008-03-01
- First posted
- 2004-08-11
- Last updated
- 2010-01-12
- Results posted
- 2009-12-21
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00089648. Inclusion in this directory is not an endorsement.